Benefits
DashboardNot registered yet? Get a free account.
Sign UpNot registered yet? Get a free account.
Sign Up
You're about to leave our website and go to an external link. Are you sure?
Skites Pharma Private Limited, is an unlisted private company incorporated on 16 March, 2017. It is classified as a private limited company and is located in Mumbai City, Maharashtra. It's authorized share capital is INR 7.00 cr and the total paid-up capital is INR 5.94 cr.
Skites Pharma's operating revenue range is Over INR 500 cr for the financial year ending on 31 March, 2023. It's EBITDA has increased by 427.55% over the previous year. At the same time, it's book networth has decreased by 13.56%.
Read more
Buy Dashboard using Credits
This action will use 1 of your credits. Are you sure you want to go ahead?
Credits Balance:
0
** All rupee values in INR crores. Based on March 2024 numbers.
1.33%
-138.49%
-21.66%
9.97%
-11.65%
0.12
-0.8
-0.29
-11.96
-6.76
1.27
Buy Report or Plans
Company dashboard
Five year financials and ratios
Risk analysis
Interactive charts
All financials
All annual returns
MoA and AoA
Latest financials
Latest annual return
MoA and AoA
Five year financials and ratios
Shareholding and group structure
Litigation and more
Everything in financial report
Peers and financials
* GST not included
** Reports & MCA filings will be based on the latest available financials.
India
(13)
| State | Type | Address |
|---|
Locations on Map
Filter (4)
Severe Risk
Moderate Risk
Low Risk
Read more
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|
| Sales | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating profit | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net profit | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Gross margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Networth | |||||
| Borrowings | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Debt to equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Current ratio | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| ROE | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Days payable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| WC days | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|
| Equity Capital | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Reserves | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Borrowings + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Long term borrowings | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Short term borrowings | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Trade payables + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Days payable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other liabilities + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other non-current liabilities | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other current liabilities | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total liabilities | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Fixed Assets + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Tangible assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| CWIP | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Intangible assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| LT loans and advances | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other non-current assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Current assets + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Inventories | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Trade receivables | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Cash and cash equivalents | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| ST loans and advances | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other current assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|
| Sales + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Sales growth % | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Expenses + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Cost of goods | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Employee cost | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other costs | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating profit + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating margin % | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other income | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Interest | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Depreciation | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Exceptional items | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Profit before tax | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Tax | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Profit - disc. ops | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net profit | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net margin % | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|
| Solvency + | |||||
| Total Debt/Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net Debt/Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total Debt/Assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total Assets/Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Liquidity + | |||||
| Current Ratio | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Quick Ratio | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Interest Coverage | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Performance | |||||
| Gross Margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating Margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net Margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Return + | |||||
| Return on Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Pre-tax ROCE | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Return on Assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Pre-tax ROIC | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Efficiency + | |||||
| Days Payable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Days Inventory | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Days Receivable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Fixed Asset Turnover | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total Asset Turnover | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Working Capital | |||||
| Cash Conversion Cycle | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Working Capital Days | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
HDFC Bank Limited
No. of Loans: 1
Total Amount : 79.9 cr
| Designation | Name | DIN/PAN | Tenure |
|---|---|---|---|
| Director | Samir Jayantilal Shah
Shareholder
|
00157396 | 8 years |
| Director | Mahesh Kantilal Shah
Shareholder
|
00506695 | 7 years |
| Director | Rohan Mahesh Shah
Shareholder
|
02867201 | 8 years |
| Director | Eishi Takahide Maekawa | 09205459 | 3 years |
| Name | Status | Paid up Capital | Common Directors | Address |
|---|---|---|---|---|
| CHAITANYA LIFE SCIENCE PRIVATE LIMITED |
Active
|
1.5 Cr | 1 | Gujarat |
| JAPOSHA TRADING PRIVATE LIMITED |
Converted to LLP
|
1.2 L | 1 | Maharashtra |
| PRAGATI PHARMA PRIVATE LIMITED |
Converted to LLP
|
12.0 L | 1 | Maharashtra |
| ASHOK GNXT PHARMA PRIVATE LIMITED |
Active
|
1.0 L | 4 | Gujarat |
| S KANT INDIA PRIVATE LIMITED |
Active
|
1.0 L | 4 | Maharashtra |
| SKITES RETAIL PRIVATE LIMITED |
Active
|
1.0 L | 3 | Maharashtra |
| JAPOSHA TRADING LLP |
Active
|
1.2 L | 1 | Maharashtra |
| SHROFF PHARMA LLP |
Active
|
1.0 L | 2 | Maharashtra |
| SEVANTILAL KANTILAL PRIVATE LIMITED |
Active
|
12.0 L | 1 | Maharashtra |
| S KANT HEALTHCARE LIMITED |
Active
|
98.0 L | 2 | Maharashtra |
| ANUH PHARMA LIMITED |
Active
|
25.1 Cr | 1 | Maharashtra |
| ESKAY IODINE PRIVATE LIMITED |
Active
|
4.0 Cr | 1 | Maharashtra |
| S KANT CHEMICALS PRIVATE LIMITED |
Active
|
1.0 L | 1 | Maharashtra |
| Name | State / Country | Incorporation Year | Paidup Capital |
|---|---|---|---|
| SHroff Pharma | India | - | - |
| SKITES RETAIL PRIVATE LIMITED | Maharashtra | 2021 | ₹ 1.0 L |
| ASHOK GNXT PHARMA PRIVATE LIMITED | Gujarat | 2019 | ₹ 1.0 L |
| S KANT INDIA PRIVATE LIMITED | Maharashtra | 2023 | ₹ 1.0 L |
The incorporation date of SKITES PHARMA PRIVATE LIMITED is 16 March, 2017
The authorized share capital of SKITES PHARMA PRIVATE LIMITED is INR ₹ 7.0 Cr.
The paid-up capital of SKITES PHARMA PRIVATE LIMITED is INR ₹ 5.9 Cr.
The registered address of SKITES PHARMA PRIVATE LIMITED is FLR-G, 15, MEHTA MAHAL, P L KHANDKE MARG MATHEW ROAD, OPERA HOUSE, GIRGAON MUMBAI Mumbai City Maharashtra - 400004
The CIN number of SKITES PHARMA PRIVATE LIMITED is U24304MH2017PTC292537.
Expand
Delete
Collapse
See
details
